Literature DB >> 18444831

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Michael Saag1, Rukmini Balu, Elizabeth Phillips, Philip Brachman, Claudia Martorell, William Burman, Britt Stancil, Michael Mosteller, Cindy Brothers, Paul Wannamaker, Arlene Hughes, Denise Sutherland-Phillips, Simon Mallal, Mark Shaefer.   

Abstract

BACKGROUND: Although the human leukocyte antigen (HLA)-B*5701 is highly associated with a hypersensitivity reaction (HSR) to abacavir (ABC), variable sensitivities have been reported when clinical data alone have been used to define an ABC HSR. This study evaluated the sensitivity of detection of the HLA-B*5701 allele as a marker of ABC HSRs in both white and black patients, using skin patch testing to supplement clinical diagnosis.
METHODS: White and black patients, identified through chart review, were classified as having received a diagnosis of an ABC HSR based on clinical findings only (a clinically suspected ABC HSR) or based on clinical findings and a positive skin patch test result (an immunologically confirmed [IC] ABC HSR). Control subjects were racially matched subjects who tolerated ABC for >/=12 weeks without experiencing an ABC HSR. Patients and control subjects were tested for the presence of HLA-B*5701. Sensitivity, specificity, and odds ratios for the detection of HLA-B*5701 as a marker for an ABC HSR were calculated for white and black participants.
RESULTS: Forty-two (32.3%) of 130 white patients and 5 (7.2%) of 69 black patients who met the criteria for clinically suspected HSRs had IC HSRs. All 42 white patients with IC HSRs were HLA-B*5701 positive (sensitivity, 100%; odds ratio, 1945; 95% confidence interval, 110-34,352). Among all white patients with clinically suspected HSRs, sensitivity was 44% (57 of 130 patients tested positive for HLA-B*5701); specificity among white control subjects was 96%. Five of 5 black patients with IC HSRs were HLA-B*5701 positive (sensitivity, 100%; odds ratio, 900; 95% confidence interval, 38-21,045). Among black patients with clinically suspected HSRs, the sensitivity was 14% (10 of 69 tested positive for HLA-B*5701); specificity among black control subjects was 99%.
CONCLUSIONS: Although IC ABC HSRs are uncommon in black persons, the 100% sensitivity of HLA-B*5701 as a marker for IC ABC HSRs in both US white and black patients suggests similar implications of the association between HLA-B*5701 positivity and risk of ABC HSRs in both races.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444831     DOI: 10.1086/529382

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  115 in total

1.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

Review 2.  Antiretroviral therapy: current drugs.

Authors:  Alice K Pau; Jomy M George
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

3.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

4.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Authors:  Guinevere Q Lee; Suzanne McCluskey; Yap Boum; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; Xiaojiang Gao; P Richard Harrigan; Jessica E Haberer; Mark J Siedner
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

Review 6.  Personalized medicine: is it a pharmacogenetic mirage?

Authors:  Rashmi R Shah; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

Review 7.  [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review].

Authors:  S Ständer; D Metze; T Luger; T Schwarz
Journal:  Hautarzt       Date:  2013-08       Impact factor: 0.751

Review 8.  Controversies in drug allergy: Testing for delayed reactions.

Authors:  Elizabeth J Phillips; Paul Bigliardi; Andreas J Bircher; Ana Broyles; Yoon-Seok Chang; Wen-Hung Chung; Rannakoe Lehloenya; Maja Mockenhaupt; Jonny Peter; Munir Pirmohamed; Jean-Claude Roujeau; Neil H Shear; Luciana Kase Tanno; Jason Trubiano; Rocco Valluzzi; Annick Barbaud
Journal:  J Allergy Clin Immunol       Date:  2018-12-17       Impact factor: 10.793

9.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.